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A systematic review and meta-analyses were undertaken to investigate the association of 16 
SLC11A1 genetic variants with disease occurrence. Literature searching indentified 109 17 
publications to include in the meta-analyses assessing the association of 11 SLC11A1 variants 18 
with autoimmune and infectious disease. The (GT)n promoter alleles 2 and 3 (rs534448891), 19 
which alter SLC11A1 expression, were significantly associated with tuberculosis [OR=1.47 20 
(1.30-1.66), OR=0.76 (0.65-0.89), respectively] and infectious disease [OR=1.25 (1.10-1.42), 21 
OR=0.83 (0.74-0.93), respectively]. However, while no association was observed with 22 
autoimmune disease, a modest significant association was observed with Type 1 diabetes 23 
[allele 2 OR=0.94 (0.89-0.98)]. Based on the stronger association of (GT)n allele 2 with 24 
tuberculosis, compared to the protective effect of allele 3, we hypothesise that allele 2 is 25 
likely the disease causing variant influencing disease susceptibility. Significant associations 26 
were observed between the 469+14G/C polymorphism (rs3731865) and autoimmune disease 27 
[OR=1.30 (1.04-1.64)] and rheumatoid arthritis [OR=1.60 (1.20-2.13)] and between the -28 
237C/T polymorphism (rs7573065) and inflammatory bowel disease [OR=0.60 (0.43-0.84)]. 29 
Further, significant associations were identified between the 469+14G/C, 1730G/A and 30 
1729+55del4 polymorphisms (rs3731865, rs17235409 and rs17235416, respectively) and 31 
both infectious disease per se and tuberculosis. These findings show a clear association 32 




Solute Carrier Family 11A Member 1 (SLC11A1), formerly NRAMP1, plays an 35 
immunomodulatory role in influencing macrophage activation status and the T helper 1/T 36 
helper 2 bias. SLC11A1 appears to have multiple functions, playing a role in both the 37 
resolution of infections and erythrophagocytosis.1-5 Localised to the endosomal/lysosomal 38 
compartment of macrophages, SLC11A1 functions as a divalent cation symporter6; 7 which, 39 
when recruited to the phagosomal membrane, transports ions out of the phagosome along the 40 
proton gradient.8-10 SLC11A1 elicits a range of pleiotropic effects on macrophage function, 41 
including increased expression of pro-inflammatory cytokines (interleukin [IL]-1β and 42 
tumour necrosis factor [TNF]-α), production of pro-inflammatory effector molecules 43 
(increased inducible nitric oxide synthase (iNOS) expression, resulting in increased L-44 
arginine flux, and subsequent production of nitric oxide (NO) and oxidative burst), and 45 
modulation of an adaptive immune response (increased MHC Class II expression and 46 
enhanced antigen presentation to T cells).11-15 How divalent cation transport by SLC11A1 47 
mediates tThese pleiotropic effects is currently unknown (i.e. a direct effect or secondary 48 
result of SLC11A1 activity), however, these pleiotropic effects are essential in the resolution 49 
of infection and also in the initiation and perpetuation of Th1 mediated autoimmune diseases. 50 
 51 
Due to the immunomodulatory capabilities of SLC11A1, the encoding gene is a strong 52 
candidate influencing autoimmune and infectious disease susceptibility. Infectious and 53 
autoimmune diseases are complex multi-factorial diseases with multiple genetic (both host 54 
and pathogen) and environmental factors playing an aetiological role. An understanding of 55 
the host genetic factors involved in these complex diseases will help to develop new 56 
preventative and therapeutic strategies. While murine models show a strong correlation 57 
between the expression of functional Slc11a1 and both resistance to macrophage-tropic 58 
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pathogens and susceptibility to autoimmune disease,1; 5; 16-18 familial and case control 59 
association studies analysing the association of SLC11A1 variants with disease incidence in 60 
humans have produced inconsistent results. 61 
 62 
Of the most commonly assessed SLC11A1 variants, the polymorphic (GT)n microsatellite 63 
repeat has been shown to alter the level of SLC11A1 expression,19; 20 and is therefore a strong 64 
candidate for influencing disease incidence. Several alleles of different repeat length have 65 
been identified, with (GT)n allele 2 conferring lower SLC11A1 expression compared to the 66 
more commonly occurring (GT)n allele 3. It has therefore been hypothesised that allele 3 67 
would provide protection against infectious disease by driving high SLC11A1 expression and 68 
a resultant Th1 mediated immune response. However, allele 3 would also be associated with 69 
an increased susceptibility to Th1-mediated autoimmune diseases.19 Other SLC11A1 variants, 70 
including the -237C/T promoter and 1730G/A (D543N) polymorphisms, have also been 71 
suggested to modulate expression or alter the functional capacity of SLC11A1 to transport 72 
divalent cations, respectively.20; 21 While several meta-analyses assessing the association of 73 
SLC11A1 polymorphisms with the incidence of tuberculosis [(GT)n repeat, 1730G/A and 2 74 
additional variants]22-26 and autoimmune disease [(GT)n repeat only]27; 28 have been 75 
completed, no study to date has systematically reviewed the literature and completed meta-76 
analyses for all SLC11A1 polymorphisms (Figure 1). The objective of this study was to 77 
systematically review the literature to identify all case-control association studies and where 78 
possible complete meta-analyses to determine if SLC11A1 variants are associated with 79 
autoimmune and infectious disease occurrence. 80 
 81 
The current meta-analysis was undertaken for a number of reasons. Firstly, there has been a 82 
doubling in the number of case control association studies completed since the most current 83 
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meta-analysis of the association of the (GT)n promoter polymorphism with autoimmune 84 
disease incidence was completed.27; 28 Secondly, the current meta-analysis is more inclusive 85 
than all other meta-analyses, including all infectious diseases (excluding viruses). Previous 86 
meta-analyses have only assessed pulmonary tuberculosis publications.22-26 Finally, this 87 
meta-analysis assessed a number of polymorphisms within SLC11A1 for which meta-analyses 88 
to determine disease association had not been previously performed due to insufficient 89 
numbers of published studies. Specifically, we present novel findings of the association of 17 90 
SLC11A1 variants with autoimmune and infectious diseases. 91 
 92 
Overall, the present study constitutes the largest and most inclusive meta-analysis examining 93 
the association of SLC11A1 polymorphisms with the incidence of infectious and autoimmune 94 
diseases conducted to date. Furthermore, based on the findings, inferences about possible 95 




A total of 131 case control studies were identified through literature searches and cross-98 
referencing, of which 117 publications were included in the meta-analysis as they assessed 99 
the association of SLC11A1 variants with autoimmune or infectious disease (Figure 2, Table 100 
S1-S3). A further 8 publications were excluded from the analysis due to duplicate reporting 101 
of identical data. From the 36 identified publications covering autoimmune disease, 11 102 
SLC11A1 polymorphisms had been investigated in a sufficient number of association studies 103 
to allow completion of a meta-analysis (a total of 160 associations) (Table 1). Of the 84 104 
publications investigating infectious disease, 10 SLC11A1 variants had been examined in a 105 
sufficient number of case control studies to perform meta-analyses (274 associations in total) 106 
(Table 1). 107 
 108 
Associations of the (GT)n promoter variants with the incidence of autoimmune disease. 109 
Meta-analyses assessing the association of SLC11A1 (GT)n alleles 2 and 3 with autoimmune 110 
disease (28 datasets) yielded non-significant pooled OR estimates of 0.93 (CI:0.83-1.05) and 111 
1.07 (0.94-1.22) (Table 2, S4 and S5). Analysis of the funnel plots from the meta-analyses 112 
did not indicate bias within the datasets. Further analysis of the association of (GT)n allele 3 113 
with individual autoimmune diseases found a significant association with the incidence of 114 
Type 1 diabetes [pooled OR estimates 1.07 (1.01-1.12)] (Table 2). Conversely, the 115 
association of (GT)n allele 2 with the incidence of Type 1 diabetes showed a significant 116 
protective effect [OR = 0.94 (CI: 0.89-0.98)] (Table 2). No association was observed between 117 
either (GT)n allele 2 or 3 and the occurrence of, specifically, inflammatory bowel disease, 118 
rheumatoid arthritis, multiple sclerosis and sarcoidosis (Table 2). When stratified according 119 
to ethnicity, a significant association was observed between both alleles 3 [OR = 1.75 (1.19-120 
2.59)] and 2 [protective effect OR = 0.58 (0.35-0.96)] and autoimmune disease incidence in 121 
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the African population, however, similar findings were not observed in either of the Asian, 122 
European or Mediterranean populations (Table 3). 123 
 124 
The 469+14G/C (INT4) variant is significantly associated with the incidence of 125 
autoimmune disease and IBDRheumatoid Arthritis  126 
Prior to this study, the (GT)n promoter polymorphism had been the only SLC11A1 genetic 127 
variant to be analysed for association with autoimmune disease, as there were insufficient 128 
association studies on other SLC11A1 variants to enable meta-analyses to be completed.28 In 129 
addition to the (GT)n repeat polymorphism (Table 2, S6-S15), we report, for the first time, the 130 
results of meta-analyses assessing the associations of 10 additional SLC11A1 variants with 131 
autoimmune disease. Analysis of the 469+14G/C (INT4) polymorphism identified that the 132 
less frequent C variant was significantly associated with the occurrence of autoimmune 133 
disease [OR = 1.30 (1.04-1.64)] (Table 2, S8). Surprisingly, the observed association of the C 134 
variant with disease occurrence is in opposition to the significant protective effect identified 135 
in the large sample size (n = 8787 cases, 10611 controls) of the study of Yang and co-136 
workers.29 Re-analysis in the absence of this large study did not alter the observed association 137 
[OR = 1.39 (1.24-1.56)]. Further analysis of the 469+14G/C polymorphism identified a 138 
significant association between the less frequent C variant and the occurrence of rheumatoid 139 
arthritis [OR = 1.60 (1.20-2.13)], but not sarcoidosis (Table 2).  140 
 141 
No significant associations were identified between the SLC11A1 polymorphisms, -237C/T, 142 
274C/T, 577-18G/A, 823C/T, 1029C/T, 1465-85G/A, 1730G/A, 1729+55del4 and 143 
1729+271del4, and the incidence of autoimmune disease (Table 2). However, while the -144 
237C/T polymorphism was not associated with autoimmune disease as a whole, further 145 
analysis of the -237C/T polymorphism found that the less frequent T variant exerted a 146 
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putative protective effect over the onset of inflammatory bowel disease (combined Crohn’s 147 
disease and ulcerative colitis) [OR = 0.60 (0.43-0.84)]. 148 
 149 
Associations of the (GT)n promoter variants with the incidence of infectious disease 150 
The meta-analyses of the association of (GT)n alleles 2 and 3 with the incidence of infectious 151 
disease included 19 and 25 datasets, respectively (Table 1, S16 and S17). The meta-analyses 152 
showed that (GT)n allele 2 was significantly associated with the incidence of infectious 153 
disease [OR = 1.25 (1.10-142)], while (GT)n allele 3 was shown to be protective against the 154 
occurrence of infectious disease [OR = 0.83 (0.74-0.93)] (Table 4). An analysis of the funnel 155 
plots indicated the presence of bias within the datasets (See Table S16 and S17). While the 156 
trim and fill method was previously used to adjust for bias,28 use of the trim and fill method 157 
in the current analysis was not required, since, if the funnel plots did not show bias (i.e. the 158 
"missing" studies were filled in), they would be located in a position that would strengthen 159 
the pooled OR estimate. 160 
 161 
Further analysis of the association of (GT)n alleles 2 and 3 with the incidence of tuberculosis 162 
alone, revealed a stronger association than those observed with the occurrence of infectious 163 
disease per se, with fixed and random-effects pooled ORs of 1.47 (1.30-1.66) and 0.75 (0.69-164 
0.82), respectively (Table 4). A meta-analysis assessing the association of (GT)n allele 2 with 165 
the occurrence of infectious disease or tuberculosis alone has not been completed prior to the 166 
current study. Previous meta-analyses,22; 26 and case control association studies have focused 167 
primarily on the association of allele 3 with infectious disease, and have not investigated 168 
allele 2 in this context. However, tThe results of the current meta-analysis show that the 169 
association of (GT)n allele 2 with the incidence of tuberculosis alone is more significant than 170 
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the protective effect putatively exerted by (GT)n allele 3. No association was identified 171 
between (GT)n allele 3 and the incidence of Leprosy (Table 4). 172 
 173 
Stratification of the data based on ethnicity found that (GT)n allele 2 was significantly 174 
associated with infectious disease susceptibility in the African population, with a 175 
susceptibility trend that failed to reach significance among the Asian and European 176 
populations (Table 3). Furthermore, no association was found in the South American 177 
population. Allele 3 was found to be significantly associated with resistance to infectious 178 
disease in the African and Asian populations, however no association was found among the 179 
European and South American populations (Table 3). While the lack of association of both 180 
(GT)n alleles 2 and 3 with the occurrence of infectious disease in the South American 181 
population may be due to the small numbers of publications completed to date (n=2), 182 
conflicting results were observed with the association of the (GT)n alleles with infectious 183 
disease in the European population. The results from the European population indicate that 184 
allele 2 may be associated with the incidence of infectious disease (OR=1.24), while allele 3 185 
appears to play no role in affording disease protection (OR=1.01), suggesting allele 2 exerts a 186 
greater influence over infectious disease susceptibility in the European population, compared 187 
to allele 3. 188 
 189 
The 469+14G/C, 1730G/A and 1729+55del4 polymorphisms are associated with the 190 
incidence of infectious disease 191 
Meta-analyses assessing the association of the 469+14G/C, 1730G/A and 1729+55del4 192 
polymorphisms with the incidence of infectious disease included 47, 54 and 52 datasets, 193 
respectively (Table 1, S20, S24 and S25). The meta-analyses revealed that the presence of the 194 
less frequent variant for each polymorphism was significantly associated with the incidence 195 
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of infectious disease, with random effects pooled OR estimates of 1.27 (1.12-1.43), 1.23 196 
(1.08-1.40) and 1.25 (1.13-1.38) for the 469+14G/C, 1730G/A and 1729+55del4 197 
polymorphisms, respectively (Table 4). Furthermore, analysis of the association of the 198 
469+14G/C, 1730G/A and 1729+55del4 polymorphisms with the incidence of tuberculosis 199 
alone identified a significant association consistent with previous meta-analyses,23; 24; 26 with 200 
OR estimates of 1.31, 1.24 and 1.31, respectively (Table 4). Significant heterogeneity, as 201 
determined by the Cochran Q value, was identified within the datasets of the meta-analyses 202 
assessing both infectious disease and tuberculosis alone for all three polymorphisms (Table 203 
4). No association between the occurrence of the 1729+55del4 polymorphism and the 204 
incidence of leprosy was identified (Table 4). No asymmetry was identified in the data from 205 
the analysis of the funnel plots for the 469+14G/C, 1730G/A and 1729+55del4 206 
polymorphisms. 207 
 208 
Analysis of the association of the 469+14G/C, 1730G/A and 1729+55del4 polymorphisms 209 
with the occurrence of infectious disease among different ethnicities identified a trend in 210 
which the less frequent variant for each polymorphism was associated with the incidence of 211 
infectious disease (Table 3). In particular, a significant association was identified between 212 
each polymorphism and the incidence of infectious disease in the Asian population. The 213 
469+14C/C and 17291730G/A+55del4 polymorphisms were significantly associated with the 214 
incidence of infectious disease in the African population. However, a protective effect 215 
appeared to be conferred by the less frequent 1730 A variant in the Mediterranean population 216 
(Table 6). However, this analysis incorporated only two publications, suggesting that the 217 




No significant association was identified between the occurrence of the -237C/T, 274C/T, 220 
577-18G/A, 823C/T, 1485-85G/A and 1729+271del4 polymorphisms and the incidence of 221 
infectious disease or tuberculosis alone (Table 4, S18, S19, S21-23 and S26). The association 222 
of the -237C/T polymorphism with infectious disease incidencetuberculosis failed to reach 223 
statistical significance and this is likely attributable to the small number of publications that 224 
have been completed to date. The results suggest that the -237C/T promoter polymorphism 225 
may be associated with the occurrence of infectious diseasetuberculosis, however more 226 




The current study aimed to determine the association of genetic variants throughout the 229 
SLC11A1 locus with the occurrence of infectious and autoimmune disease. This meta-230 
analysis incorporates the largest number of publications (120 publications, 23 individual 231 
meta-analyses) and the largest number of SLC11A1 polymorphisms investigated to date, with 232 
21 SLC11A1 polymorphisms analysed with the occurrence of autoimmune (10/21) and 233 
infectious (11/21) disease, respectively, 17 of which have not been previously analysed. The 234 
results of the current meta-analyses have shown that genetic variants throughout SLC11A1 235 
are associated with the incidence of both infectious and autoimmune disease (Figure 3). Of 236 
the 17 new SLC11A1 variants assessed, this meta-analysis has identified a significant 237 
association between the 469+14G/C polymorphism and the incidence of autoimmune disease 238 
as a whole and rheumatoid arthritis in particular, and the -273C/T polymorphism with the 239 
occurrence of inflammatory bowel disease. Similar to previous meta-analyses, the current 240 
analysis did not identify a significant association between either (GT)n allele 2 or 3 with a 241 
reduced or increased incidence of autoimmune disease, respectively.28 However, stratification 242 
according to disease did identify a significant association with Type 1 diabetes incidence, 243 
suggesting that the (GT)n polymorphism may exert a minor effect on some autoimmune 244 
diseases. 245 
 246 
The 469+14G/C, 1730G/A and 1729+55del4 polymorphisms were significantly associated 247 
with the incidence of infectious disease as a whole and with tuberculosis in particular, with 248 
pooled OR estimates determined in the current analyses being similar to previously reported 249 
OR estimates.23; 24 Similarly, consistent with previous reports, (GT)n allele 3 was found to be 250 
significantly protective of infectious disease and tuberculosis, while, for the first time, a 251 
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significant association between (GT)n allele 2 and an increased susceptibility to infectious 252 
disease and tuberculosis was shown to exist. 253 
 254 
A meta-analysis assessing the association of (GT)n allele 2 with the occurrence of infectious 255 
disease or tuberculosis alone has not been completed prior to the current study. Previous 256 
meta-analyses,23; 24; 26 and case control association studies, have focused primarily on the 257 
association of allele 3 with infectious disease,30-35 and associations of allele 2 with infectious 258 
disease incidence have not been investigated. However, the results of the current meta-259 
analysis show that the association of (GT)n allele 2 with the incidence of tuberculosis alone is 260 
more significant than the protective effect putatively exerted by (GT)n allele 3. This data 261 
suggests that allele 2 may exert a greater influence on the incidence of infectious disease than 262 
the previously thought (GT)n allele 3.19 263 
 264 
Reporter studies have shown that different lengths of the (GT)n promoter microsatellite repeat 265 
alter SLC11A1 expression levels, with (GT)n allele 3 driving higher expression than (GT)n 266 
allele 2. Due to the important role SLC11A1 plays in initiating and perpetuating a Th1 267 
immune response, itSeale and Blackwell was hypothesised that over expression of SLC11A1, 268 
driven by (GT)n allele 3 would result in a heightened Th1 immune response and a subsequent 269 
“chronic hyperactivation of macrophages” (i.e. classical activation).19; 39 This chronic 270 
hyperactivation of macrophages would confer resistance to infectious disease, but also 271 
susceptibility to autoimmune diseases. While the current analysis shows an association 272 
between the (GT)n alleles and infectious disease (in particular tuberculosis), no association 273 
was evident with autoimmune disease per se, however a minor effect was observed with 274 




The current analyses identified that allele 2 of the (GT)n repeat had a stronger association 277 
with tuberculosis susceptibility than the protective effect afforded by allele 3. This was 278 
highlighted in the European population, where allele 2 showed a trend for increased 279 
susceptibility to tuberculosis, however, allele 3 showed no protective effect. Additionally, the 280 
(GT)n allele 2 dataset was found to be homogenous (X2 = 12.23, p = 0.27), however, 281 
heterogeneity was identified within the (GT)n allele 3 dataset, as well as all other variants 282 
associated with tuberculosis (Table 4). It is envisaged that a sequence variant which alters the 283 
propensity of an individual to contract an infectious disease like tuberculosis (i.e. the variant 284 
provides a selective advantage or disadvantage to the carrier) would be common to all studies 285 
irrespective of other factors responsible for heterogeneity (like ethnicity or nutritional status). 286 
In such a case, the ORs for the individual studies in the meta-analysis would be expected to 287 
be homogenous, as is observed with the meta-analysis examining the association of allele 2 288 
with the incidence of tuberculosis. Therefore, the data suggests that allele 2 may exert a 289 
greater influence on the incidence of infectious disease than the previously thought (GT)n 290 
allele 3. Due to this stronger association, we hypothesise that (GT)n allele 2, and not allele 3, 291 
is the disease causing variant at the (GT)n microsatellite, which exerts the selective pressure 292 
at the SLC11A1 locus to influence infectious disease susceptibility. 293 
 294 
The question then arises as to how might (GT)n allele 2 function to alter infectious and 295 
autoimmune disease susceptibility? Reporter studies show different SLC11A1 expression 296 
levels in the presence of different (GT)n alleles, with (GT)n allele 2 driving lower expression 297 
than (GT)n allele 3 (refs). The (GT)n microsatellite has endogenous transcriptional enhancer 298 
activity due to the ability of the repetitive GT units to form Z-DNA.36; 37 Furthermore, Alleles 299 
2 and 3 which differ by a single 2bp GT repeat are reported to influence transcription through 300 





factors HIF-1α and ATF-3/JunB have been shown to bind with-in and adjacent to the (GT)n 302 
repeat, respectively.36-38 Thus altered transcription factor binding, in the presence of the 303 
different repeat lengths may alter SLC11A1 expression to influence macrophage phenotype 304 
and susceptibly to infectious and autoimmune disease. Indeed, murine studies show modest 305 
reductions in Slc11a1 expression result in significant phenotypic consequences,2; 4; 16 306 
suggesting a similar reduction in SLC11A1 promoter activity with (GT)n allele 2 will also 307 
result in an altered cellular phenotype to influence disease susceptibility. Consistent with this 308 
hypothesis is the observation that allele 2 carriers have increased expression of the anti-309 
inflammatory cytokine IL-10, compared to individuals who do not carry allele 2,39 and 310 
murine macrophages which lack functional Slc11a1 show higher IL-10 expression after 311 
infectious challenge.11; 18; 40-43 312 
 313 
Human and murine studies suggest that (GT)n allele 2 may alter disease susceptibility through 314 
higher expression of the anti-inflammatory cytokine, IL-10. Macrophages or dendritic cells 315 
isolated from mice which lack functional Slc11a1 show higher IL-10 expression after 316 
infectious challenge, or induction of a model of autoimmune disease, compared to 317 
macrophages/dendritic cells containing functional Slc11a1.11; 18; 40-43 While the loss of 318 
functional Slc11a1 in the murine model does not correlate with the observed phenotypic 319 
changes in SLC11A1 expression occurring with the different (GT)n repeat alleles in humans 320 
(i.e. a reduced level of SLC11A1 expression rather than loss of function), a human based 321 
study has identified allele 2 carriers to have increased expression of the anti-inflammatory 322 
cytokine IL-10, compared to individuals who do not carry allele 2.44 41 It is therefore 323 
hypothesised that allele 2 is the disease causing variant at the (GT)n microsatellite repeat 324 






increased IL-10 expression would produce a heightened anti-inflammatory immune response, 326 
inhibiting the production of an adequate Th1 pro-inflammatory immune response. 327 
 328 
Specifically, IL-10 has been shown to inhibit innate macrophage anti-microbial molecules 329 
involved in a pro-inflammatory immune response and has also been shown to reduce antigen 330 
processing, antigen presentation and T cell activation.44-49 Thus, the inhibition of a Th1 pro-331 
inflammatory immune response, in the presence of allele 2 (conferring lower SLC11A1 332 
expression), would confer susceptibility to infectious disease, while in the presence of (GT)n 333 
allele 3 an adequate level of SLC11A1 expression would exist, high enough to produce a Th1 334 
pro-inflammatory immune response to allow efficient resolution of infectious disease. This 335 
could possibly explain why meta-analyses show significant associations between variants at 336 
the (GT)n polymorphism with incidence of infectious disease with only very modest 337 
associations with autoimmune disease, specifically Type 1 diabetes. Future work should aim 338 
to explore further the role of (GT)n allele 2 in infectious disease occurrence. 339 
 340 
The current meta-analysis identified positive associations between polymorphisms within the 341 
5’ region of SLC11A1, but not within the 3’ region, and the incidence of autoimmune disease, 342 
while polymorphisms located in the 5’ and 3’ regions of SLC11A1 were associated with the 343 
incidence of infectious disease (Figure 4). Previous publications have identified the existence 344 
of significant linkage disequilibrium (LD) between the (GT)n, -237C/T, 274C/T and 345 
469+14G/C variants and markers 110kb upstream of the SLC11A1 locus, including the IL8Rb 346 
locus (termed 5’LD haplotype end). Furthermore, significant LD has been observed between 347 
the 823C/T, 1465-85G/A, 1730G/A and 1729+55del4 variants and markers 110kb 348 
downstream of the SLC11A1 locus (termed 3’LD haplotype end). However, LD is not 349 
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observed between variants located in the 5’ and 3’ LD haplotype ends of the SLC11A1 locus 350 
(Figure 4).44 351 
 352 
The SLC11A1 polymorphisms identified to be significantly associated with disease incidence 353 
in the current analysis may be the functional cause of the association(s), or, alternatively, the 354 
associations observed may be due to the particular polymorphism being either positively or 355 
negatively selected because it is in LD with the true disease causing variant. In the latter case, 356 
a genetic variant which alters disease incidence provides either a positive or negative 357 
selective pressure for the inheritance of all of the neutral variants within that LD block 358 
(hitchhiker effect).45 Due to the complex LD pattern which exists at the SLC11A1 locus,44; 46-359 
48 the findings suggest that at least one functional polymorphism exists within the 5’ LD 360 
region of SLC11A1, which alters the cellular phenotype to influence autoimmune disease 361 
susceptibility, while at least two functional polymorphisms, one in the 5’ region and a second 362 
in the 3’ region, influence the occurrence of infectious disease (Figure 4). Thus 363 
polymorphisms in LD with the significantly associated SLC11A1 polymorphisms should also 364 
be considered as potential functional candidates for disease susceptibility. However, the 365 
observed associations with infectious and autoimmune disease are most likely mediated by a 366 
polymorphism(s) within the SLC11A1 locus given the role SLC11A1 plays in the activation 367 
of a Th1 (pro-inflammatory) immune response, and not due to variants located in the LD 368 
regions but outside of the SLC11A1 locus. 369 
 370 
Of the SLC11A1 variants significantly associated with infectious disease, the (GT)n and the 371 
1730G/A polymorphisms are putative candidates for the alteration of disease incidence 372 
observed at the 5’ and 3’ LD ends, respectively. These two polymorphisms are likely 373 
candidates as they have putative functional effects, being able to either influence the level of 374 
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SLC11A1 expressed19; 20 or alter the ability of SLC11A1 to transport divalent cations,21; 49 375 
respectively. These putative functional effects result in an altered phenotype, which may 376 
explain the reason for the associations with infectious disease identified in this study. 377 
 378 
Of all polymorphisms examined, the 469+14G/C is the only variant to show an association 379 
with the incidence of both autoimmune and infectious disease and is therefore another 380 
potential disease causing variant within the 5’ LD block of SLC11A1. Surprisingly, the C 381 
variant was associated with increased risk of developing both infectious and autoimmune 382 
disease. The 469+14G/C polymorphism is located in intron 4 of SLC11A1, near an 383 
alternatively spliced exon designated 4a, that produces a truncated transcript and non-384 
functional protein. It has been suggested that the 469+14G/C polymorphism may alter the 385 
ratio of truncated to functional transcripts (which is normally relatively low at approximately 386 
1:5).50 However, Yang and co-workers did not identify any difference in SLC11A1 expression 387 
or the ratio of truncated to functional transcripts between differing genotypes of the 388 
469+14G/C polymorphism,29 suggesting that the 469+14G/C polymorphism may influence 389 
SLC11A1 function through an as yet unidentified mechanism. Further functional tests are 390 
required to identify the polymorphic variants that may result in an altered cellular phenotype 391 
to influence infectious/autoimmune disease susceptibility. 392 
 393 
Future association studies should ideally analyse cases and controls through haplotype 394 
analyses, rather than adopting a narrow binomial approach of analysing only single 395 
polymorphisms. For example, while the current meta-analyses suggest an association 396 
between the (GT)n repeat and the incidence of infectious disease, the (GT)n repeat does not 397 
function independently to alter SLC11A1 expression, as reporter studies show that both the 398 
(GT)n and -237C/T polymorphisms function synergistically to determine SLC11A1 399 
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expression levels.20 Therefore, association studies which analyse the effect of the (GT)n 400 
repeat and -237C/T polymorphisms independently will not be able to assess the complex 401 
interaction that determines the level of SLC11A1 expressed. Additionally, there are other 402 
polymorphisms within SLC11A1 that putatively exert phenotypic effects to alter SLC11A1 403 
expression/function (e.g. 1730G/A). Therefore, an individual’s propensity to develop disease 404 
would be determined by a summation of the effects of each of the individual polymorphisms 405 
within the SLC11A1 locus. Testament to this, association studies which have assessed 406 
SLC11A1 haplotypes have identified more robust associations.30; 51-55 407 
 408 
Additionally, while some polymorphisms have been assessed in a large number of association 409 
studies to allow the completion of a meaningful meta-analysis, there were still insufficient 410 
association studies completed for several polymorphisms which showed a trend with disease 411 
incidence, however, the pooled OR estimates did not reach significance. It is possible that the 412 
existence of more association studies may have allowed statistical significance to be attained. 413 
This includes, for example, analyses of the association of the -237C/T and 1029C/T (A318V) 414 
polymorphisms with the incidence of tuberculosis and autoimmune disease, respectively. 415 
Both of these polymorphisms may exert effects on SLC11A1 expression/function and show a 416 
significant trend with disease incidence, but in the absence of sufficient numbers of studies, 417 
the existence of significant associations cannot be determined. Furthermore, the current 418 
case/control literature has focused solely on the effect of SLC11A1 on pro-inflammatory (M1) 419 
macrophages with disease occurrence and it is unclear the effect that SLC11A1 variation may 420 
have on M2 macrophages and disease. For example, given the role SLC11A1 plays in 421 








The aim of this work was to determine, based on previously published case control 424 
association studies, the association of SLC11A1 polymorphisms with the incidence of 425 
infectious and autoimmune disease. Of the 23 datasets covering 11 SLC11A1 variants, 426 
associations were found for 9, with 4 of the 23 datasets investigated showing trends, possibly 427 
due to the low numbers of association studies available. Based on the findings of the current 428 
meta-analyses, the SLC11A1 locus appears to play a role in influencing susceptibility to both 429 
infectious and autoimmune diseases. The findings of this meta-analysis are significant in 430 
helping to determine the multiple host genetic factors involved in complex diseases. 431 
Identification of these host genetic factors will help to prevent, control and treat these 432 
complex diseases.  433 
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MATERIALS AND METHODS 434 
Literature Search and Inclusion Criteria 435 
Publications included in the meta-analysis were identified by searching literature databases 436 
(PubMed, Medline/Ovid, Chinese National Knowledge Infrastructure (CNKI) and Asia/China 437 
on demand) using the search terms “SLC11A1”, “NRAMP1”, “autoimmunity”, 438 
“tuberculosis” and “infection”, individually and in combination (from 1996-2012). 439 
Additional papers were sourced by cross-referencing original and review publications. 440 
Inclusion criteria for the meta-analysis were that studies assessed SLC11A1 polymorphisms 441 
in patients diagnosed with a specific autoimmune or infectious disease and used non-familial 442 
subjects as controls. Studies analysing cancer, viral infections or pathology due to infection 443 
were excluded. Furthermore, all publications included in the meta-analyses had to assess HIV 444 
negative cases and controls. When duplicate association studies were encountered, studies 445 
published in English or containing the more informative data were included in the analyses. 446 
 447 
Data Collection 448 
Information regarding the disease studied, the population analysed and the study findings 449 
were extracted from all publications meeting the inclusion criteria. Total study numbers 450 
(individuals and alleles) and allelic frequencies (numbers and percentages) were also 451 
tabulated for all relevant datasets within a publication. When a publication contained several 452 
datasets/associations for a single polymorphism, each dataset was assessed as an individual 453 
association when the populations/diseases were different between the datasets. Alternatively, 454 
data was pooled if the same population/disease was analysed. Allele frequencies were 455 
inferred from genotype frequencies when reported. In the few cases where carrier frequencies 456 
were reported, the genotype frequencies were first determined and then allele frequencies 457 
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were inferred. Corresponding authors were contacted by email if the information to determine 458 
the odds ratio (OR) was unavailable or if the published data was ambiguous. When 459 
publications assessed specific SLC11A1 polymorphisms, but concluded that an analysis was 460 
not completed due to a low frequency of the less commonly occurring variant, the data was 461 
omitted from the analysis. The data extracted from all publications satisfying the inclusion 462 
criteria for the meta-analysis was reanalysed to ensure that the extracted data was correct. 463 
 464 
Statistical Analyses 465 
Statistical analyses were completed using the Rmeta package in the program R.56; 57 Using the 466 
relevant data sets, the OR and 95% confidence intervals (CI) were determined for each 467 
individual association included in each of the meta-analyses. Associations which contained 468 
zero observations for both cases and controls were excluded from analyses, while the 469 
reciprocal of the opposite treatment size method was used to allow studies with a zero 470 
observation in either case or control groups to be included.58 471 
 472 
The association of a polymorphism with disease incidence, from the individual associations, 473 
was completed by the determination of the fixed-effects pooled OR estimate (Mantel-474 
Haenszel method). The Cochran Q test was utilised to determine whether heterogeneity was 475 
present in the analysed data set. If the Cochran Q test identified the presence of heterogeneity 476 
within the dataset, the random-effects pooled OR estimate (DerSimonian-Laird method) was 477 
determined. Pooled OR were determined from studies grouped irrespective of clinical 478 
manifestation. Funnel plots were assessed to determine the presence of publication bias. 479 
 480 
Only polymorphisms that had been investigated in three or more individual association 481 
studies were included in the analysis. Where a large number of datasets were available for a 482 
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particular polymorphism, smaller meta-analyses were completed, where possible, analysing 483 
the association of individual diseases (for example Type 1 diabetes, tuberculosis), or 484 
geographical location, with the SLC11A1 polymorphisms. In these cases, analyses were 485 
performed from as many as two association studies. 486 
 487 
Although nine alleles of a polymorphic SLC11A1 promoter (GT)n microsatellite repeat 488 
(rs534448891) have been identified to date, seven of these alleles (alleles 1 and 4-9) occur at 489 
low frequencies. Therefore, association studies have focused on the association of the most 490 
common alleles 2 and 3 with disease occurrence. Meta-analyses of both (GT)n allele 3 and 491 
allele 2 were completed to determine the association of these alleles with the incidence of 492 
autoimmune and infectious disease. For the analysis of allele 3, the frequency data for alleles 493 
1, 2 and 4-9 were pooled and compared against the frequency of allele 3. Likewise, for the 494 
analysis of allele 2, the frequencies of alleles 1 and 3-9 were pooled and compared against the 495 
frequency of allele 2.  496 
 24 
 
SUPPLEMENTARY INFORMATION 497 
Supplementary information is available at the Genes and Immunity website. Supplementary 498 
information includes 26 tables, forest and funnel plots of each meta-analysis and references 499 




The authors wish to thank Jenefer M. Blackwell, Anna Dubaniewicz, A M Graham, Leonardo 502 
A Sechi, Lee E Sieswerda, Maria Gazouli, Margje Haverkamp, Linda Wicker, Jennie Yang, 503 
Eileen Hoal, Timothy Sterling and Alison Motsinger-Reif for supplying additional population 504 
data. Nicholas Archer was funded through an Australian Postgraduate Award. The authors 505 
declare no conflicts of interest. 506 
CONFLICT OF INTEREST 507 




1. Vidal S, Tremblay ML, Govoni G, Gauthier S, Sebastiani G, Malo D, et al. The 510 
Ity/Lsh/Bcg locus: natural resistance to infection with intracellular parasites is abrogated by 511 
disruption of the Nramp1 gene. J Exp Med 1995; 182(3): 655-66. 512 
2. Soe-Lin S, Apte SS, Andriopoulos BJ, Andrews MC, Schranzhofer M, Kahawita T, et 513 
al. Nramp1 promotes efficient macrophage recycling of iron following erythrophagocytosis 514 
in vivo. Proc Natl Acad Sci U S A 2009; 106(14): 5960-5. 515 
3. Soe-Lin S, Apte SS, Mikhael MR, Kayembe LK, Nie G, Ponka P. Both Nramp1 and 516 
DMT1 are necessary for efficient macrophage iron recycling. Exp Hematol 2010; 38(8): 609-517 
17. 518 
4. Soe-Lin S, Sheftel AD, Wasyluk B, Ponka P. Nramp1 equips macrophages for 519 
efficient iron recycling. Exp Hematol 2008; 36(8): 929-37. 520 
5. Govoni G, Vidal S, Gauthier S, Skamene E, Malo D, Gros P. The Bcg/Ity/Lsh locus: 521 
genetic transfer of resistance to infections in C57BL/6J mice transgenic for the Nramp1 522 
Gly169 allele. Infect Immun 1996; 64(8): 2923-9. 523 
6. Forbes JR, Gros P. Iron, manganese, and cobalt transport by Nramp1 (Slc11a1) and 524 
Nramp2 (Slc11a2) expressed at the plasma membrane. Blood 2003; 102(5): 1884-92. 525 
7. Goswami T, Bhattacharjee A, Babal P, Searle S, Moore E, Li M, et al. Natural-526 
resistance-associated macrophage protein 1 is an H+/bivalent cation antiporter. Biochem J 527 
2001; 354(3): 511–19. 528 
8. Forbes JR, Gros P. Divalent-metal transport by NRAMP proteins at the interface of 529 
host-pathogen interactions. Trends Microbiol 2001; 9(8): 397-403. 530 
9. Frehel C, Canonne-Hergaux F, Gros P, de Chastellier C. Effect of Nramp1 on 531 
bacterial replication and on maturation of Mycobacterium avium-containing phagosomes in 532 
bone marrow-derived mouse macrophages. Cellular Microbiol 2002; 4(8): 541-56. 533 
 27 
 
10. Jabado N, Jankowski A, Dougaparsad S, Picard V, Grinstein S, Gros P. Natural 534 
resistance to intracellular infections: natural resistance-associated macrophage protein 1 535 
(NRAMP1) functions as a pH-dependent manganese transporter at the phagosomal 536 
membrane. J Exp Med 2000; 192(9): 1237-48. 537 
11. Stober CB, Brode S, White JK, Popoff JF, Blackwell JM. Slc11a1, Formerly Nramp1, 538 
Is Expressed in Dendritic Cells and Influences Major Histocompatibility Complex Class II 539 
Expression and Antigen-Presenting Cell Function. Infect Immun 2007; 75(10): 5059-67. 540 
12. Blackwell JM. Structure and function of the natural-resistance-associated macrophage 541 
protein (Nramp1), a candidate protein for infectious and autoimmune disease susceptibility. 542 
Mol Med Today 1996; 2(5): 205-11. 543 
13. Karupiah G, Hunt NH, King NJ, Chaudhri G. NADPH oxidase, Nramp1 and nitric 544 
oxide synthase 2 in the host antimicrobial response. Rev Immunogenet 2000; 2(3): 387-415. 545 
14. Zwilling BS, Vespa L, Massie M. Regulation of I-A expression by murine peritoneal 546 
macrophages: differences linked to the Bcg gene. J Immunol 1987; 138(5): 1372-6. 547 
15. Soo SS, Villarreal-Ramos B, Khan CMA, Hormaeche CE, Blackwell JM. Genetic 548 
Control of Immune Response to Recombinant Antigens Carried by an Attenuated Salmonella 549 
typhimurium Vaccine Strain: Nramp1 Influences T-Helper Subset Responses and Protection 550 
against Leishmanial Challenge. Infect Immun 1998; 66(5): 1910-7. 551 
16. Kissler S, Stern P, Takahashi K, Hunter K, Peterson LB, Wicker LS. In vivo RNA 552 
interference demonstrates a role for Nramp1 in modifying susceptibility to type 1 diabetes. 553 
Nat Genet 2006; 38(4): 479-83. 554 
17. Malo D, Vogan K, Vidal S, Hu J, Cellier M, Schurr E, et al. Haplotype Mapping and 555 
Sequence Analysis of the Mouse Nramp Gene Predict Susceptibility to Infection with 556 
Intracellular Parasites. Genomics 1994; 23(1): 51-61. 557 
 28 
 
18. Jiang HR, Gilchrist DS, Popoff J-F, Jamieson SE, Truscott M, White JK, et al. 558 
Influence of Slc11a1 (formerly Nramp1) on DSS-induced colitis in mice. J Leukoc Biol 2009; 559 
85(4): 703-10. 560 
19. Searle S, Blackwell JM. Evidence for a functional repeat polymorphism in the 561 
promoter of the human NRAMP1 gene that correlates with autoimmune versus infectious 562 
disease susceptibility. J Med Genet 1999; 36(4): 295-9. 563 
20. Zaahl MG, Robson KJH, Warnich L, Kotze MJ. Expression of the SLC11A1 564 
(NRAMP1) 5 '-(GT)(n) repeat: Opposite effect in the presence of-237C → T. Blood Cells Mol 565 
Dis 2004; 33(1): 45-50. 566 
21. Decobert M, Larue H, Bergeron A, Harel F, Pfister C, Rousseau F, et al. 567 
Polymorphisms of the human NRAMP1 gene are associated with response to bacillus 568 
Calmette-Guerin immunotherapy for superficial bladder cancer. J Urol 2006; 175(4): 1506-569 
11. 570 
22. Li HT, Zhang TT, Huang QH, Lv B, Huang J. Meta-analysis on NRAMP1 gene 571 
polymorphisms and tuberculosis susceptibility in East-Asia population. Zhonghua Liu Xing 572 
Bing Xue Za Zhi 2006; 27(5): 428-32. 573 
23. Li HT, Zhang TT, Zhou YQ, Huang QH, Huang J. SLC11A1 (formerly NRAMP1) 574 
gene polymorphisms and tuberculosis susceptibility: a meta-analysis. Int J Tuberc Lung Dis 575 
2006; 10(1): 3-12. 576 
24. Li X, Yang Y, Zhou F, Zhang Y, Lu H, Jin Q, et al. SLC11A1 (NRAMP1) 577 
Polymorphisms and Tuberculosis Susceptibility: Updated Systematic Review and Meta-578 
Analysis. PLoS ONE 2011; 6(1): e15831. 579 
25. Zhao ZZ, Zhang TZ, Gao YM. Meta-analysis on the association of the association 580 
between the polymorphisms of the NRAMP1 genes and tuberculosis susceptibility. Modern 581 
Preventive Medicine 2010; 37(15): 2801-18. 582 
 29 
 
26. Meilang Q, Zhang Y, Zhang J, Zhao Y, Tian C, Huang J, et al. Polymorphisms in the 583 
SLC11A1 gene and tuberculosis risk: a meta-analysis update. Int J Tuberc Lung Dis 2012; 584 
16(4): 437-46. 585 
27. Nishino M, Ikegami H, Fujisawa T, Kawaguchi Y, Kawabata Y, Shintani M, et al. 586 
Functional polymorphism in Z-DNA–forming motif of promoter of SLC11A1 gene and type 587 
1 diabetes in Japanese subjects: Association study and meta-analysis Metabolism 2005; 588 
54(5): 628-33. 589 
28. O'Brien BA, Archer NS, Simpson AM, Torpy FR, Nassif NT. Association of 590 
SLC11A1 promoter polymorphisms with the incidence of autoimmune and inflammatory 591 
diseases: A meta-analysis. J Autoimmun 2008; 31(1): 42-51. 592 
29. Yang JH, Downes K, Howson JM, Nutland S, Stevens HE, Walker NM, et al. 593 
Evidence of association with type 1 diabetes in the SLC11A1 gene region. BMC Med Genet 594 
2011; 12: 59. 595 
30. Bellamy R, Ruwende C, Corrah T, McAdam K, Whittle HC, Hill AVS. Variations in 596 
the Nramp1 gene and susceptibility to tuberculosis in West Africans. N Engl J Med 1998; 597 
338(10): 640-4. 598 
31. Soborg C, Andersen AB, Madsen HO, Kok-Jensen A, Skinhoj P, Garred P. Natural 599 
resistance-associated macrophage protein 1 polymorphisms are associated with microscopy-600 
positive tuberculosis. J Infect Dis 2002; 186(4): 517-21. 601 
32. Fitness J, Floyd S, Warndorff DK, Sichali L, Malema S, Crampin AC, et al. Large-602 
scale candidate gene study of tuberculosis susceptibility in the Karonga district of northern 603 
Malawi. Am J Trop Med Hyg 2004; 71(3): 341-9. 604 
33. Fitness J, Floyd S, Warndorff DK, Sichali L, Mwaungulu L, Crampin AC, et al. 605 
Large-scale candidate gene study of leprosy susceptibility in the Karonga district of northern 606 
Malawi. Am J Trop Med Hyg 2004; 71(3): 330-40. 607 
 30 
 
34. Leung KH, Yip SP, Wong WS, Yiu LS, Chan KK, Lai WM, et al. Sex- and age-608 
dependent association of SLC11A1 polymorphisms with tuberculosis in Chinese: a case 609 
control study. BMC Infect Dis 2007; 7: :19. 610 
35. Soborg C, Andersen AB, Range N, Malenganisho W, Friis H, Magnussen P, et al. 611 
Influence of candidate susceptibility genes on tuberculosis in a high endemic region. Mol 612 
Immunol 2007; 44(9): 2213-20. 613 
36. Bayele HK, Peyssonnaux C, Giatromanolaki A, Arrais-Silva WW, Mohamed HS, 614 
Collins H, et al. HIF-1 regulates heritable variation and allele expression phenotypes of the 615 
macrophage immune response gene SLC11A1 from a Z-DNA-forming microsatellite. Blood 616 
2007; 15(8): 3039-48. 617 
37. Xu YZ, Thuraisingam T, Marino R, Radzioch D. Recruitment of SWI/SNF complex 618 
is required for transcriptional activation of SLC11A1 gene during macrophage differentiation 619 
of HL-60 cells. J Biol Chem 2011; 286(15): 12839-49. 620 
38. Taka S, Gazouli M, Politis P, Pappa K, Anagnou N. Transcription factor ATF-3 621 
regulates allele variation phenotypes of the human SLC11A1 gene. Mol Biol Rep 2013; 622 
40(3): 2263-71. 623 
39. Awomoyi AA, Marchant A, Howson JM, McAdam KP, Blackwell JM, Newport MJ. 624 
Interleukin-10, Polymorphism in SLC11A1 (formerly NRAMP1), and Susceptibility to 625 
Tuberculosis. J Infect Dis 2002; 186(12): 1808. 626 
40. Fritsche G, Nairz M, Werner ER, Barton HC, Weiss G. Nramp1-functionality 627 
increases iNOS expression via repression of IL-10 formation. Eur J Immunol 2008; 38(11): 628 
3060-7. 629 
41. Pie S, Matsiota-Bernard P, Truffa-Bachi P, Nauciel N. Gamma interferon and 630 
interleukin-10 gene expression in innately susceptible and resistant mice during the early 631 
phase of Salmonella typhimurium infection. Infect Immun 1996; 162(3): 6122-31. 632 
 31 
 
42. Rojas M, Olivier M, Gros P, Barrera LF, Garcia LF. TNF-α and IL-10 Modulate the 633 
Induction of Apoptosis by Virulent Mycobacterium tuberculosis in Murine Macrophages. J 634 
Immunol 1999; 162(10): 6122-31. 635 
43. Smit JJ, van Loveren H, Hoekstra MO, Nijkamp FP, Bloksma N. Influence of the 636 
macrophage bacterial resistance gene Nramp1 (Slc11a1) on the induction of allergic asthma 637 
in the mouse. FASEB J 2003; 17(8): 958-60. 638 
44. Yip SP, Leung KH, Lin CK. Extent and distribution of linkage disequilibrium around 639 
the SLC11A1 locus. Genes Immun 2003; 4(3): 212-21. 640 
45. Smith JM, Haigh J. The hitch-hiking effect of a favourable gene. Genet Res 1974; 641 
23(01): 23-35. 642 
46. Dunstan SJ, Ho VA, Duc CM, Lanh MN, Phuong CX, Luxemburger C, et al. Typhoid 643 
Fever and Genetic Polymorphisms at the Natural Resistance Associated Macrophage Protein 644 
1. J Infect Dis 2001; 183(7): 1156-60. 645 
47. Kim E, Kim K, Park S, Kim J, Lee W, Cha S, et al. SLC11A1 Polymorphisms Are 646 
Associated with the Risk of Chronic Obstructive Pulmonary Disease in a Korean Population. 647 
Biochem Genet 2008; 46(7): 506-19. 648 
48. Mehrotra S, Oommen J, Mishra A, Sudharshan M, Tiwary P, Jamieson S, et al. No 649 
evidence for association between SLC11A1 and visceral leishmaniasis in India. BMC Med 650 
Genet 2011; 12(1): 71. 651 
49. Gazouli M, Atsaves V, Mantzaris G, Economou M, Nasioulas G, Evangelou K, et al. 652 
Role of functional polymorphisms of NRAMP1 gene for the development of Crohn's disease. 653 
Inflamm Bowel Dis 2008; 14(10): 1323-30. 654 
50. Cellier M, Govoni G, Vidal S, Kwan T, Groulx N, Liu J, et al. Human natural 655 
resistance-associated macrophage protein: cDNA cloning, chromosomal mapping, genomic 656 
organization, and tissue-specific expression. J Exp Med 1994; 180(5): 1741-52. 657 
 32 
 
51. Runstadler JA, Säilä H, Savolainen A, Leirisalo-Repo M, Aho K, Tuomilehto-Wolf E, 658 
et al. Association of SLC11A1 (NRAMP1) with persistent oligoarticular and polyarticular 659 
rheumatoid factor-negative juvenile idiopathic arthritis in Finnish patients: Haplotype 660 
analysis in Finnish families. Arthritis Rheum 2005; 52(1): 247-56. 661 
52. Yen JH, Lin CH, Tsai WC, Ou TT, Wu CC, Hu CJ, et al. Natural resistance-662 
associated macrophage protein 1 gene polymorphisms in rheumatoid arthritis. Immunol Lett 663 
2006; 102(1): 91-7. 664 
53. Kim JH, Lee SY, Lee SH, Sin C, Shim JJ, In KH, et al. NRAMP1 genetic 665 
polymorphisms as a risk factor of tuberculous pleurisy. Int J Tuberc Lung Dis 2003; 7(4): 666 
370-5. 667 
54. Qu Y, Tang Y, Cao D, Wu F, Liu J, Lu G, et al. Genetic polymorphisms in alveolar 668 
macrophage response-related genes, and risk of silicosis and pulmonary tuberculosis in 669 
Chinese iron miners. Int J Hyg Environ Health 2007; 210(6): 679-89. 670 
55. Merza M, Farnia P, Anoosheh S, Varahram M, Kazampour M, Pajand O, et al. The 671 
NRAMP1, VDR and TNF-alpha gene polymorphisms in Iranian tuberculosis patients: the 672 
study on host susceptibility. Braz J Infect Dis 2009; 13(4): 252-6. 673 
56. Lumley T. Rmeta version 2.14, R package, 2009, http://cran.r-project.org. 674 
57. R Development Core Team. R: A language and environment for statistical computing, 675 
Vienna, Austria, 2008, http://www.R-project.org. 676 
58. Sweeting JM, Sutton JA, Lambert CP. What to add to nothing? Use and avoidance of 677 
continuity corrections in meta-analysis of sparse data. Stat Med 2004; 23(9): 1351-75. 678 
 679 
  680 
 33 
 
FIGURE LEGENDS 681 
Figure 1  682 
Location of SLC11A1 polymorphisms analysed in the meta-analysis. Associations between 683 
the occurrence of these polymorphisms and the incidence of autoimmune and infectious 684 
disease were analysed using meta-analyses. The 15 exons of the gene are shown as black 685 
boxes with their respective numbers. The corresponding scale above indicates the length (kb) 686 
of the gene. The grey boxes indicate the 3’ and 5’ untranslated regions and the introns and 687 
flanking regions are represented by a thin line. The arrows indicate the position of sequence 688 
variants. Below each polymorphism is the reference SNP (rs#) identification number. Genetic 689 
variants shown in italics are those for which meta-analyses have previously been performed. 690 
 691 
Figure 2 692 
Results of the search strategy showing the number of case control publications identified and 693 
excluded from the meta-analyses. 694 
 695 
Figure 3 696 
Summary of the results from the meta-analyses (pooled OR estimates and 95% CI interval) 697 
assessing the association of the different SLC11A1 polymorphisms with the incidence of 698 
autoimmune disease, infectious disease and tuberculosis alone. 699 
 700 
Figure 4 701 
Linkage disequilibrium at the SLC11A1 locus and location of polymorphisms associated with 702 
the incidence of autoimmune and infectious disease. (A) Genomic organisation of SLC11A1 703 
and location of studied sequence variants. The 15 exons of the gene are shown as black boxes 704 
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with their respective numbers and the corresponding scale above indicates the length (kb) of 705 
the gene. The grey boxes indicate the 3’ and 5’ untranslated regions and the introns and 706 
flanking regions are represented by a thin line. The arrows indicate the position of sequence 707 
variants. (B) LD located within the SLC11A1 locus. The blue circles indicate the location of 708 
the SLC11A1 polymorphisms, with the thin line representing the flanking DNA regions. The 709 
two LD blocks (termed 5’ LD haplotype end and 3’ LD haplotype end) are shown, with the 710 
double dashed line designating the weak LD observed between 5’ and 3’ SLC11A1 regions. 711 
(C) Polymorphisms within the 5’ LD haplotype end but not the 3’ end are associated with the 712 
incidence of autoimmune disease (red circles indicate an association, while white circles 713 
indicate no association). (D) Polymorphisms in both the 5’ and 3’ LD haplotype blocks were 714 
found to be associated with infectious disease. The (GT)n and 469+14G/C; and 1730G/A are 715 
candidate polymorphisms in the SLC11A1 locus influencing autoimmune and infectious 716 




Table 1: Summary of Identified Publications, Datasets Analysed and Numbers of Cases and Controls. 
Polymorphism 
Autoimmune Disease Infectious Disease 
Publications1 Datasets2 Analysed3 Cases Controls Publications1 Datasets2 Analysed3 Cases Controls 
(GT)n allele 3 29 31 28 10602 10797 29 30 25 5411 6118 
(GT)n allele 2 29 31 28 10664 10919 29 30 19 3753 3622 
-237C/T 7 9 9 6408 6233 7 8 6 1321 1425 
274C/T 9 9 9 6546 7074 13 15 14 2847 3593 
469+14G/C 15 15 15 10806 12540 48 52 47 7029 8170 
577-18G/A 6 6 5 711 691 3 3 3 162 291 
823C/T 8 8 8 922 952 4 4 3 270 355 
1029C/T 7 7 4 850 775      
1465-85G/A 9 8 8 6342 6639 7 8 7 1705 1690 
1730G/A 17 16 16 8010 8149 55 59 54 8174 8698 
1729+55del4 18 17 16 10321 11790 56 58 52 8864 10290 
1729+271del4 3 3 3 480 309 6 7 7 1648 2455 
1 Total number of published studies identified from the literature search meeting the inclusion criteria of the meta-analysis. 
2 Total number of datasets from the identified publications for inclusion into the meta-analysis. 
3 The number of datasets analysed in the meta-analysis after the removal of datasets containing zero observations for both cases and controls and 
when data to determine OR was not forthcoming from corresponding authors. 
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Table 2: Pooled OR estimates of the association of SLC11A1 polymorphisms with the 
incidence of autoimmune disease. 
Polymorphism Test of heterogeneity 
X2 (P-value) 
Pooled OR estimate 
(CI)  Association 
(GT)n allele 3 93.77 (p < 0.01) 1.07 (0.94-1.22)2 
 IBD 17.71 (p = 0.01) 1.05 (0.81-1.37)2 
 MS 12.80 (p < 0.01) 1.22 (0.80-1.85)2 
 RA 18.08 (p < 0.01) 1.06 (0.75-1.51)2 
 SA 30.06 (p < 0.01) 1.16 (0.59-2.28)2 
 T1D 1.68 (p = 0.64) 1.07 (1.01-1.12)1 
   
(GT)n allele 2 73.35 (p < 0.01) 0.93 (0.83-1.05)2 
 IBD 4.70 (p = 0.70) 0.91 (0.78-1.06) 
 MS 14.58 (p < 0.01) 0.84 (0.53-1.33)2 
 RA 15.48 (p < 0.01) 0.91 (0.65-1.26)2 
 SA 24.43 (p < 0.01) 0.96 (0.52-1.80)2 
 T1D 3.91 (p = 0.27) 0.94 (0.89-0.98)1 
   
-237C/T 12.43 (p = 0.13) 0.92 (0.83-1.02) 
 IBD 5.82 (p = 0.32) 0.60 (0.43-0.84)1 
   
274C/T 18.41 (p = 0.01) 1.16 (0.96-1.40)2 
   
469+14G/C 86.50 (p < 0.01) 1.30 (1.04-1.64)1,2 
 RA 1.82 (p = 0.61) 1.60 (1.20-2.13)1 
 SA 21.17 (p < 0.01) 1.07 (0.53-2.18)2 
   
577-18G/A 2.87 (p = 0.58) 0.74 (0.50-1.09) 
   
823C/T 23.71 (p < 0.01) 1.02 (0.67-1.56)2 
   
1029C/T 1.57 (p = 0.67) 0.48 (0.21-1.11) 
   
1465-85G/A 10.98 (p = 0.14) 0.98 (0.93-1.03) 
   
1730G/A 46.45 (p < 0.01) 1.14 (0.86-1.51)2 
 RA 14.45 (p < 0.01) 1.29 (0.62-2.68)2 
   
1729+55del4 34.75 (p < 0.01) 1.21 (0.96-1.54)2 
 RA 19.09 (p < 0.01) 1.52 (0.67-3.44)2 
   
1729+271del4 1.79 (p = 0.41) 0.98 (0.80-1.22) 
IBD: inflammatory bowel disease, MS: multiple sclerosis, RA: rheumatoid arthritis, SA: 
sarcoidosis, T1D: Type 1 diabetes. 
1 Statistically significant (p < 0.05, bold). 
2 Random-effects pooled OR estimate. 
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Table 3: Pooled OR estimates of the association of SLC11A1 variants and disease occurrence stratified by ethnicity. 
Ethnicity 
Autoimmune disease Infectious disease 
(GT)n allele 3 (GT)n allele 2 (GT)n allele 3 (GT)n allele 2 469+14G/C 1730G/A 1729+55del4 
African 1.75 (1.19-2.59)1 0.58 (0.35-0.96)1 0.80 (0.66-0.97)1,2 1.45 (1.22-1.71)1 1.37 (1.14-1.65)1 1.57 (1.11-2.24)1,2 1.11 (1.00-1.21) 
Asian 0.85 (0.69-1.03) 0.86 (0.68-1.09) 0.76 (0.64-0.92)1,2 1.23 (0.98-1.53)2 1.53 (1.15-2.04)1,2 1.33 (1.14-1.55)1,2 1.34 (1.16-1.57)1,2 
European 1.17 (0.97-1.42)2 0.84 (0.70-1.01)2 1.01 (0.69-1.48)2 1.24 (0.97-1.57) 1.08 (0.93-1.24) 0.95 (0.72-1.25) 1.49 (0.87-2.14) 
Mediterranean 0.97 (0.74-1.30)2 1.14 (0.89-1.45)2   1.06 (0.79-1.41) 0.38 (0.24-0.59)1 0.92 (0.40-2.14) 
South American   1.02 (0.74-1.41) 1.00 (0.72-1.40)  1.16 (0.96-1.41) 1.21 (1.00-1.47) 
1 Statistically significant (p < 0.05, bold). 
2 Random-effects pooled OR estimate.
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Table 4: Pooled OR estimates of the association of SLC11A1 polymorphisms with the 
incidence of infectious disease. 
Polymorphism Test of heterogeneity  
X2 (P-value) 
Pooled OR estimate 
(CI)  Association 
(GT)n allele 3 61.93 (p < 0.01) 0.83 (0.74-0.93)1,2 
 Mycobacterium spp. 58.73 (p < 0.01) 0.82 (0.71-0.95)1,2 
 Tuberculosis 40.54 (p < 0.01) 0.76 (0.65-0.89)1,2 
 Leprosy 4.48 (p = 0.11) 1.11 (0.92-1.35) 
   
(GT)n allele 2 30.77 (p = 0.03) 1.25 (1.10-1.42)1 
 Mycobacterium spp. 20.80 (p = 0.07) 1.37 (1.23-1.53)1 
 Tuberculosis 12.23 (p = 0.27) 1.47 (1.30-1.66)1 
   
-237C/T 6.33 (p = 0.28) 1.03 (0.83-1.29) 
 Tuberculosis 1.37 (p = 0.50) 0.63 (0.37-1.08) 
   
274C/T 17.33 (p = 0.18) 1.01 (0.92-1.11) 
 Tuberculosis 13.19 (p = 0.07) 1.12 (0.91-1.37) 
   
469+14G/C 115.8 (p < 0.01) 1.27 (1.12-1.43)1,2 
 Mycobacterium spp. 109.16 (p < 0.01) 1.30 (1.13-1.49)1,2 
 Tuberculosis 21.17 (p < 0.01) 1.31 (1.12-1.54)1,2 
 Leprosy 4.34 (p = 0.11) 1.22 (0.85-1.76) 
   
577-18G/A3 1.28 (p = 0.53) 0.96 (0.60-1.55) 
   
823C/T3 7.63 (p = 0.02) 0.67 (0.29-1.53)2b 
   
1465-85G/A 3.40 (p = 0.76) 1.00 (0.90-1.11) 
 Tuberculosis 2.85 (P=0.58) 1.05 (0.88-1.26) 
   
1730G/A 128.81 (p < 0.01) 1.23 (1.08-1.40)1,2 
 Mycobacterium spp. 125.59 (p < 0.01) 1.26 (1.09-1.46)1,2 
 Tuberculosis 101.93 (p < 0.01) 1.24 (1.07-1.44)1,2 
   
1729+55del4 112.86 (p < 0.01) 1.25 (1.13-1.38)1,2 
 Mycobacterium spp. 109.47 (p < 0.01) 1.27 (1.14-1.41)1,2 
 Tuberculosis 79.11 (p < 0.01) 1.31 (1.18-1.46)1,2 
 Leprosy 1.63 (p = 0.80) 1.06 (0.89-1.26) 
   
1729+271del4 4.53 (p = 0.61) 1.00 (0.91-1.11) 
 Tuberculosis 2.12 (p = 0.71) 1.02 (0.87-1.19) 
1 Statistically significant (p < 0.05, bold). 
2 Random-effects pooled OR estimate. 
3 Publications only analyse tuberculosis. 
 
 
 
